JP2017523169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523169A5 JP2017523169A5 JP2017502192A JP2017502192A JP2017523169A5 JP 2017523169 A5 JP2017523169 A5 JP 2017523169A5 JP 2017502192 A JP2017502192 A JP 2017502192A JP 2017502192 A JP2017502192 A JP 2017502192A JP 2017523169 A5 JP2017523169 A5 JP 2017523169A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- group
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 229910052801 chlorine Inorganic materials 0.000 claims description 24
- 229910052731 fluorine Inorganic materials 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 241000711904 Pneumoviridae Species 0.000 claims description 10
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims description 10
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 10
- 229920002554 vinyl polymer Polymers 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 10
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 9
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 8
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 claims description 8
- 241000282412 Homo Species 0.000 claims description 7
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 4
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 229910019946 S-S Inorganic materials 0.000 claims description 2
- 229910019939 S—S Inorganic materials 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims 1
- 0 *C1(*)[C@](C2=C*c3c(N)nc(*)nc23)O[C@](*)(CO)[C@@]1O* Chemical compound *C1(*)[C@](C2=C*c3c(N)nc(*)nc23)O[C@](*)(CO)[C@@]1O* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 241000711920 Human orthopneumovirus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N c1ccc(cncc2)c2c1 Chemical compound c1ccc(cncc2)c2c1 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N c1ccc2ncccc2c1 Chemical compound c1ccc2ncccc2c1 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462029896P | 2014-07-28 | 2014-07-28 | |
| US62/029,896 | 2014-07-28 | ||
| PCT/US2015/041574 WO2016018697A1 (en) | 2014-07-28 | 2015-07-22 | Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncitial virus infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212344A Division JP6991188B2 (ja) | 2014-07-28 | 2019-11-25 | 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017523169A JP2017523169A (ja) | 2017-08-17 |
| JP2017523169A5 true JP2017523169A5 (enExample) | 2018-08-30 |
Family
ID=53765598
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017502192A Withdrawn JP2017523169A (ja) | 2014-07-28 | 2015-07-22 | 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２−ｄ］ピリミジン、フロ［３，２−ｄ］ピリミジン、およびピロロ［３，２−ｄ］ピリミジン |
| JP2019212344A Active JP6991188B2 (ja) | 2014-07-28 | 2019-11-25 | 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン |
| JP2021181870A Pending JP2022010149A (ja) | 2014-07-28 | 2021-11-08 | 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019212344A Active JP6991188B2 (ja) | 2014-07-28 | 2019-11-25 | 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン |
| JP2021181870A Pending JP2022010149A (ja) | 2014-07-28 | 2021-11-08 | 呼吸器合胞体ウイルス感染の処置のために有用な、チエノ［３，２－ｄ］ピリミジン、フロ［３，２－ｄ］ピリミジン、およびピロロ［３，２－ｄ］ピリミジン |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US9828388B2 (enExample) |
| EP (3) | EP3174870B1 (enExample) |
| JP (3) | JP2017523169A (enExample) |
| KR (1) | KR102460181B1 (enExample) |
| CN (1) | CN106573939B (enExample) |
| AR (1) | AR101280A1 (enExample) |
| AU (1) | AU2015298207C1 (enExample) |
| BR (1) | BR112017001565A2 (enExample) |
| CA (1) | CA2956571C (enExample) |
| EA (1) | EA032490B1 (enExample) |
| ES (2) | ES2802175T3 (enExample) |
| IL (1) | IL249706A0 (enExample) |
| MX (1) | MX2017001284A (enExample) |
| NZ (1) | NZ727996A (enExample) |
| PL (2) | PL3174870T3 (enExample) |
| PT (2) | PT3174870T (enExample) |
| SG (1) | SG11201700213SA (enExample) |
| SI (2) | SI3693367T1 (enExample) |
| TW (1) | TWI678369B (enExample) |
| WO (1) | WO2016018697A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2595980B1 (en) | 2010-07-22 | 2014-09-03 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| SMT202100592T1 (it) | 2014-12-26 | 2021-11-12 | Univ Emory | Derivati antivirali della n4-idrossicitidina |
| RU2738232C2 (ru) | 2015-07-22 | 2020-12-09 | Энанта Фармасьютикалс, Инк. | Производные бензодиазепина как ингибиторы rsv |
| US20190077797A1 (en) * | 2015-10-30 | 2019-03-14 | Ozkan SARI | Processes for preparing 2-dihalo ribolactones |
| JP7078960B2 (ja) | 2017-01-26 | 2022-06-01 | エス． トサントリゾス，ヨウラ | 置換二環式ピリミジン系化合物および組成物ならびにその使用 |
| AU2018339068B2 (en) * | 2017-09-29 | 2022-12-15 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as RSV inhibitors |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| PH12021552201A1 (en) | 2019-03-18 | 2022-05-30 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| AR121356A1 (es) | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111548384B (zh) * | 2020-03-29 | 2021-04-27 | 常州安蒂卫生物科技有限公司 | 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药 |
| WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2025072641A1 (en) * | 2023-09-28 | 2025-04-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US135A (en) | 1837-03-03 | Jesse j | ||
| US5458A (en) | 1848-02-22 | Bench-vise | ||
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (enExample) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4584369A (en) * | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| EP0940154B1 (en) | 1991-07-02 | 2007-04-18 | Nektar Therapeutics | Device for delivering aerosolized medicaments |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| CN1968605A (zh) * | 2004-06-15 | 2007-05-23 | 默克公司 | 作为rna依赖性rna病毒聚合酶抑制剂的c－嘌呤核苷类似物 |
| WO2006050161A2 (en) * | 2004-10-29 | 2006-05-11 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| AU2007333243B2 (en) | 2006-12-07 | 2013-03-14 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| PL2114980T3 (pl) | 2007-01-12 | 2012-11-30 | Biocryst Pharm Inc | Przeciwwirusowe analogi nukleozydów |
| AU2008251555B2 (en) * | 2007-05-10 | 2012-08-30 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer |
| CN100532388C (zh) | 2007-07-16 | 2009-08-26 | 郑州大学 | 2’-氟-4’-取代-核苷类似物、其制备方法及应用 |
| WO2009132123A1 (en) * | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | Carba-nucleoside analogs for antiviral treatment |
| WO2010002877A2 (en) | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| EP3150608B1 (en) | 2009-09-21 | 2019-04-10 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| NZ599404A (en) | 2009-09-21 | 2014-02-28 | Gilead Sciences Inc | Processes and intermediates for the preparation of 1’-substituted carba-nucleoside analogs |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| EP2596004B1 (en) | 2010-07-19 | 2014-09-10 | Gilead Sciences, Inc. | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| EP2595980B1 (en) * | 2010-07-22 | 2014-09-03 | Gilead Sciences, Inc. | Methods and compounds for treating paramyxoviridae virus infections |
| CN102351931B (zh) * | 2010-09-07 | 2014-01-22 | 河南省科学院高新技术研究中心 | 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用 |
| US20120077814A1 (en) | 2010-09-10 | 2012-03-29 | Zhong Wang | Sulfonamide, sulfamate, and sulfamothioate derivatives |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| EP2619206A1 (en) * | 2010-09-20 | 2013-07-31 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US8877731B2 (en) | 2010-09-22 | 2014-11-04 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| EP2627334B1 (en) | 2010-10-15 | 2015-04-29 | Biocryst Pharmaceuticals, Inc. | Compositions for use in the treatment of viral infections |
| NZ613370A (en) | 2010-12-20 | 2015-05-29 | Gilead Sciences Inc | Combinations for treating hcv |
| US9156872B2 (en) | 2011-04-13 | 2015-10-13 | Merck Sharp & Dohme Corp. | 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| CN103748098B (zh) * | 2011-10-11 | 2016-06-29 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗或预防呼吸道合胞病毒疾病的化合物 |
| CA3107640A1 (en) * | 2011-12-22 | 2013-06-27 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections |
| ES2621217T3 (es) | 2012-03-13 | 2017-07-03 | Gilead Sciences, Inc. | Análogos de carba-nucleósido 2'-sustituidos para tratamiento antivírico |
| PL2827875T3 (pl) * | 2012-03-21 | 2019-07-31 | Janssen Biopharma, Inc. | Podstawione nukleozydy, nukleotydy i ich analogi |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
-
2015
- 2015-07-08 TW TW104122181A patent/TWI678369B/zh active
- 2015-07-22 PL PL15745083T patent/PL3174870T3/pl unknown
- 2015-07-22 PT PT157450834T patent/PT3174870T/pt unknown
- 2015-07-22 MX MX2017001284A patent/MX2017001284A/es unknown
- 2015-07-22 ES ES15745083T patent/ES2802175T3/es active Active
- 2015-07-22 WO PCT/US2015/041574 patent/WO2016018697A1/en not_active Ceased
- 2015-07-22 CA CA2956571A patent/CA2956571C/en active Active
- 2015-07-22 EP EP15745083.4A patent/EP3174870B1/en active Active
- 2015-07-22 BR BR112017001565A patent/BR112017001565A2/pt not_active IP Right Cessation
- 2015-07-22 SG SG11201700213SA patent/SG11201700213SA/en unknown
- 2015-07-22 EP EP22154464.6A patent/EP4023650A1/en active Pending
- 2015-07-22 PT PT201664380T patent/PT3693367T/pt unknown
- 2015-07-22 AU AU2015298207A patent/AU2015298207C1/en active Active
- 2015-07-22 SI SI201531826T patent/SI3693367T1/sl unknown
- 2015-07-22 KR KR1020177005142A patent/KR102460181B1/ko active Active
- 2015-07-22 EA EA201790146A patent/EA032490B1/ru not_active IP Right Cessation
- 2015-07-22 CN CN201580041342.0A patent/CN106573939B/zh active Active
- 2015-07-22 US US14/806,227 patent/US9828388B2/en active Active
- 2015-07-22 EP EP20166438.0A patent/EP3693367B1/en active Active
- 2015-07-22 JP JP2017502192A patent/JP2017523169A/ja not_active Withdrawn
- 2015-07-22 ES ES20166438T patent/ES2910382T3/es active Active
- 2015-07-22 AR ARP150102330A patent/AR101280A1/es unknown
- 2015-07-22 PL PL20166438T patent/PL3693367T3/pl unknown
- 2015-07-22 SI SI201531250T patent/SI3174870T1/sl unknown
- 2015-07-22 NZ NZ727996A patent/NZ727996A/en unknown
-
2016
- 2016-12-21 IL IL249706A patent/IL249706A0/en unknown
-
2017
- 2017-09-27 US US15/717,493 patent/US10179794B2/en active Active
-
2018
- 2018-11-28 US US16/203,112 patent/US10501476B2/en active Active
-
2019
- 2019-11-25 JP JP2019212344A patent/JP6991188B2/ja active Active
-
2021
- 2021-11-08 JP JP2021181870A patent/JP2022010149A/ja active Pending
-
2024
- 2024-03-05 US US18/596,486 patent/US20250042913A1/en not_active Abandoned
- 2024-10-16 US US18/917,217 patent/US20250270229A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523169A5 (enExample) | ||
| JP2018021051A5 (enExample) | ||
| JP2017525699A5 (enExample) | ||
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| JP2016527217A5 (enExample) | ||
| JP2017537949A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2019505529A5 (enExample) | ||
| JP2014532716A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2015522650A5 (enExample) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| JP2015504081A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2019510034A5 (enExample) | ||
| JP2016537382A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2015516427A5 (enExample) | ||
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| JP2019504050A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| JP2014500296A5 (enExample) | ||
| JP2016513696A5 (enExample) | ||
| JP2017517512A5 (enExample) |